当前位置: 首页肺癌正文

人人看懂PD-1:小细胞肺癌一线数据

|2021年12月31日| 浏览:2071

图片

图片

图片

图片

参考文献

[1]Jonathan W Goldman, Mikhail Dvorkin, Yuanbin Chen, et al. Durvalumab,with or without tremelimumab,plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer(CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.The Lancet Oncology.2020.

[2]Overall survival with first-line durvalumab plus platinum-etoposide in patients with extensive-stage (ES)-SCLC in CASPIAN: Subgroup findings from Asia.2019 ESMO ASIA.

[3]Jonathan W G , Marina C G, Yuanbin Chen,et al. Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study. Lung Cancer. 2020 Nov;149:46-52.

[4]https://mp.weixin.qq.com/s/8eiE_5-f_1R658cuhw_z5Q

 

 

 

本文仅供医学药学专业人士阅读

本文来源: VIP说 发表,转载请注明来源!如有侵权请联系删除
关键词:
局晚期肝癌患者治疗,放免联合来助力,ORR近90%!
上一篇

局晚期肝癌患者治疗,放免联合来助力,ORR近90%!

2021消化道肿瘤新药研发年度盘点:HER-2焕发新活力 | 消傲江湖 第四弹
下一篇

2021消化道肿瘤新药研发年度盘点:HER-2焕发新活力 | 消傲江湖 第四弹

阅读相关文章